CBD has lower affinity for CB receptors. It functions as an antagonist or partial antagonist at endogenous cannabinoid receptors (both equally CB1 and CB2 receptor types together with other G-protein-coupled receptors [GPCRs]) by inhibiting comprehensive binding of direct ligands, and should act